Tracking Coronary Calcification and Atherosclerotic Lesions in Patients with Stable Angina Pectoris Undergoing Nifedipine Therapy
Aims: The objective of the Coronary Calcification (CC) study was to determine in patients with chronic symptomatic coronary artery disease, if, in addition to standard therapy, nifedipine GITS, relative to placebo, would arrest or slow down the progression of calcium or the development of new athero...
Gespeichert in:
| Veröffentlicht in: | Cardiology 2007-03, Vol.107 (3), p.165-171 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 171 |
|---|---|
| container_issue | 3 |
| container_start_page | 165 |
| container_title | Cardiology |
| container_volume | 107 |
| creator | Motro, Michael Kirwan, Bridget-Anne de Brouwer, Sophie Poole-Wilson, Philip A. Shemesh, Joseph |
| description | Aims: The objective of the Coronary Calcification (CC) study was to determine in patients with chronic symptomatic coronary artery disease, if, in addition to standard therapy, nifedipine GITS, relative to placebo, would arrest or slow down the progression of calcium or the development of new atherosclerotic lesions in the coronary arteries. Methods and Results: The CC study was part of the ACTION trial. Multi-slice computerized tomography was used to measure and track the progression of CC. Five hundred and eighteen patients were included in this study. The changes in calcium score from baseline every 24 months, over a period of between 4.5 and 6 years, were similar in the nifedipine and placebotreatment groups (p = 0.8). Compared to placebo, more patients in the nifedipine group (71 vs. 60%) were free of new calcified atherosclerotic lesions during follow-up(p = 0.095). Conclusion: Nifedipine GITS was not effective in slowing down the progression of calcium in advanced atherosclerotic plaques in patients with stable angina pectoris. Although statistically not significant, Nifedipine demonstrated a trend in slowing down the development of new atherosclerotic lesions. |
| doi_str_mv | 10.1159/000095308 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmed_primary_16940720</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>70342414</sourcerecordid><originalsourceid>FETCH-LOGICAL-c361t-74b4e81f349d3798ae21cdaf7f198f1e5af2bcfaae548dfad246435f0c021aba3</originalsourceid><addsrcrecordid>eNqF0UFrHCEUAGApKc0m7SHnQpEeCjlMq44zjsdlaZPA0ga6OQ9vnOfGZFY36hJy7D-vYZcEeqkHRf3eE98j5Iyzr5w3-hsrQzc1696QGZeCV1o1_IjMynFXtTUXx-QkpbuylUqKd-SYt1oyJdiM_FlFMPfOr-kixOAhPtEFTMZZZyC74Cn4kc7zLcaQzFTm7AxdYipXiTpPr4tCnxN9dPmW_s4wTEjnfu080Gs0OUSX6I0fMa7D8ys_ncXRbZ1HuipJYfv0nry1MCX8cFhPyc2P76vFZbX8dXG1mC8rU7c8V0oOEjtua6nHWukOUHAzglWW685ybMCKwVgAbGQ3WhiFbGXdWGaY4DBAfUq-7PNuY3jYYcr9xiWD0wQewy71itVSSC7_CwXTXIiuLfDzP_Au7KIvn-iFkopp1qqCzvfIlAqmiLbfRrcpde4565-71790r9hPh4S7YYPjqzy0q4CPe3APcY3xBezD_wJ9j58k</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>274709067</pqid></control><display><type>article</type><title>Tracking Coronary Calcification and Atherosclerotic Lesions in Patients with Stable Angina Pectoris Undergoing Nifedipine Therapy</title><source>MEDLINE</source><source>Karger Journals</source><creator>Motro, Michael ; Kirwan, Bridget-Anne ; de Brouwer, Sophie ; Poole-Wilson, Philip A. ; Shemesh, Joseph</creator><creatorcontrib>Motro, Michael ; Kirwan, Bridget-Anne ; de Brouwer, Sophie ; Poole-Wilson, Philip A. ; Shemesh, Joseph ; ACTION CC side-arm study</creatorcontrib><description>Aims: The objective of the Coronary Calcification (CC) study was to determine in patients with chronic symptomatic coronary artery disease, if, in addition to standard therapy, nifedipine GITS, relative to placebo, would arrest or slow down the progression of calcium or the development of new atherosclerotic lesions in the coronary arteries. Methods and Results: The CC study was part of the ACTION trial. Multi-slice computerized tomography was used to measure and track the progression of CC. Five hundred and eighteen patients were included in this study. The changes in calcium score from baseline every 24 months, over a period of between 4.5 and 6 years, were similar in the nifedipine and placebotreatment groups (p = 0.8). Compared to placebo, more patients in the nifedipine group (71 vs. 60%) were free of new calcified atherosclerotic lesions during follow-up(p = 0.095). Conclusion: Nifedipine GITS was not effective in slowing down the progression of calcium in advanced atherosclerotic plaques in patients with stable angina pectoris. Although statistically not significant, Nifedipine demonstrated a trend in slowing down the development of new atherosclerotic lesions.</description><identifier>ISSN: 0008-6312</identifier><identifier>EISSN: 1421-9751</identifier><identifier>DOI: 10.1159/000095308</identifier><identifier>PMID: 16940720</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Aged ; Angina pectoris ; Angina Pectoris - drug therapy ; Atherosclerosis - drug therapy ; Atherosclerosis - pathology ; Calcinosis - drug therapy ; Calcinosis - pathology ; Calcium Channel Blockers - therapeutic use ; Cardiology ; Coronary Vessels - pathology ; Drug therapy ; Female ; Humans ; Male ; Middle Aged ; Nifedipine - therapeutic use ; Original Research</subject><ispartof>Cardiology, 2007-03, Vol.107 (3), p.165-171</ispartof><rights>2007 S. Karger AG, Basel</rights><rights>Copyright 2007 S. Karger AG, Basel.</rights><rights>Copyright (c) 2007 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c361t-74b4e81f349d3798ae21cdaf7f198f1e5af2bcfaae548dfad246435f0c021aba3</citedby><cites>FETCH-LOGICAL-c361t-74b4e81f349d3798ae21cdaf7f198f1e5af2bcfaae548dfad246435f0c021aba3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,2425,27911,27912</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16940720$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Motro, Michael</creatorcontrib><creatorcontrib>Kirwan, Bridget-Anne</creatorcontrib><creatorcontrib>de Brouwer, Sophie</creatorcontrib><creatorcontrib>Poole-Wilson, Philip A.</creatorcontrib><creatorcontrib>Shemesh, Joseph</creatorcontrib><creatorcontrib>ACTION CC side-arm study</creatorcontrib><title>Tracking Coronary Calcification and Atherosclerotic Lesions in Patients with Stable Angina Pectoris Undergoing Nifedipine Therapy</title><title>Cardiology</title><addtitle>Cardiology</addtitle><description>Aims: The objective of the Coronary Calcification (CC) study was to determine in patients with chronic symptomatic coronary artery disease, if, in addition to standard therapy, nifedipine GITS, relative to placebo, would arrest or slow down the progression of calcium or the development of new atherosclerotic lesions in the coronary arteries. Methods and Results: The CC study was part of the ACTION trial. Multi-slice computerized tomography was used to measure and track the progression of CC. Five hundred and eighteen patients were included in this study. The changes in calcium score from baseline every 24 months, over a period of between 4.5 and 6 years, were similar in the nifedipine and placebotreatment groups (p = 0.8). Compared to placebo, more patients in the nifedipine group (71 vs. 60%) were free of new calcified atherosclerotic lesions during follow-up(p = 0.095). Conclusion: Nifedipine GITS was not effective in slowing down the progression of calcium in advanced atherosclerotic plaques in patients with stable angina pectoris. Although statistically not significant, Nifedipine demonstrated a trend in slowing down the development of new atherosclerotic lesions.</description><subject>Aged</subject><subject>Angina pectoris</subject><subject>Angina Pectoris - drug therapy</subject><subject>Atherosclerosis - drug therapy</subject><subject>Atherosclerosis - pathology</subject><subject>Calcinosis - drug therapy</subject><subject>Calcinosis - pathology</subject><subject>Calcium Channel Blockers - therapeutic use</subject><subject>Cardiology</subject><subject>Coronary Vessels - pathology</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Nifedipine - therapeutic use</subject><subject>Original Research</subject><issn>0008-6312</issn><issn>1421-9751</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqF0UFrHCEUAGApKc0m7SHnQpEeCjlMq44zjsdlaZPA0ga6OQ9vnOfGZFY36hJy7D-vYZcEeqkHRf3eE98j5Iyzr5w3-hsrQzc1696QGZeCV1o1_IjMynFXtTUXx-QkpbuylUqKd-SYt1oyJdiM_FlFMPfOr-kixOAhPtEFTMZZZyC74Cn4kc7zLcaQzFTm7AxdYipXiTpPr4tCnxN9dPmW_s4wTEjnfu080Gs0OUSX6I0fMa7D8ys_ncXRbZ1HuipJYfv0nry1MCX8cFhPyc2P76vFZbX8dXG1mC8rU7c8V0oOEjtua6nHWukOUHAzglWW685ybMCKwVgAbGQ3WhiFbGXdWGaY4DBAfUq-7PNuY3jYYcr9xiWD0wQewy71itVSSC7_CwXTXIiuLfDzP_Au7KIvn-iFkopp1qqCzvfIlAqmiLbfRrcpde4565-71790r9hPh4S7YYPjqzy0q4CPe3APcY3xBezD_wJ9j58k</recordid><startdate>200703</startdate><enddate>200703</enddate><creator>Motro, Michael</creator><creator>Kirwan, Bridget-Anne</creator><creator>de Brouwer, Sophie</creator><creator>Poole-Wilson, Philip A.</creator><creator>Shemesh, Joseph</creator><general>S. Karger AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7QP</scope><scope>7X8</scope></search><sort><creationdate>200703</creationdate><title>Tracking Coronary Calcification and Atherosclerotic Lesions in Patients with Stable Angina Pectoris Undergoing Nifedipine Therapy</title><author>Motro, Michael ; Kirwan, Bridget-Anne ; de Brouwer, Sophie ; Poole-Wilson, Philip A. ; Shemesh, Joseph</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c361t-74b4e81f349d3798ae21cdaf7f198f1e5af2bcfaae548dfad246435f0c021aba3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Aged</topic><topic>Angina pectoris</topic><topic>Angina Pectoris - drug therapy</topic><topic>Atherosclerosis - drug therapy</topic><topic>Atherosclerosis - pathology</topic><topic>Calcinosis - drug therapy</topic><topic>Calcinosis - pathology</topic><topic>Calcium Channel Blockers - therapeutic use</topic><topic>Cardiology</topic><topic>Coronary Vessels - pathology</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Nifedipine - therapeutic use</topic><topic>Original Research</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Motro, Michael</creatorcontrib><creatorcontrib>Kirwan, Bridget-Anne</creatorcontrib><creatorcontrib>de Brouwer, Sophie</creatorcontrib><creatorcontrib>Poole-Wilson, Philip A.</creatorcontrib><creatorcontrib>Shemesh, Joseph</creatorcontrib><creatorcontrib>ACTION CC side-arm study</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Biotechnology Research Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Cardiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Motro, Michael</au><au>Kirwan, Bridget-Anne</au><au>de Brouwer, Sophie</au><au>Poole-Wilson, Philip A.</au><au>Shemesh, Joseph</au><aucorp>ACTION CC side-arm study</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Tracking Coronary Calcification and Atherosclerotic Lesions in Patients with Stable Angina Pectoris Undergoing Nifedipine Therapy</atitle><jtitle>Cardiology</jtitle><addtitle>Cardiology</addtitle><date>2007-03</date><risdate>2007</risdate><volume>107</volume><issue>3</issue><spage>165</spage><epage>171</epage><pages>165-171</pages><issn>0008-6312</issn><eissn>1421-9751</eissn><abstract>Aims: The objective of the Coronary Calcification (CC) study was to determine in patients with chronic symptomatic coronary artery disease, if, in addition to standard therapy, nifedipine GITS, relative to placebo, would arrest or slow down the progression of calcium or the development of new atherosclerotic lesions in the coronary arteries. Methods and Results: The CC study was part of the ACTION trial. Multi-slice computerized tomography was used to measure and track the progression of CC. Five hundred and eighteen patients were included in this study. The changes in calcium score from baseline every 24 months, over a period of between 4.5 and 6 years, were similar in the nifedipine and placebotreatment groups (p = 0.8). Compared to placebo, more patients in the nifedipine group (71 vs. 60%) were free of new calcified atherosclerotic lesions during follow-up(p = 0.095). Conclusion: Nifedipine GITS was not effective in slowing down the progression of calcium in advanced atherosclerotic plaques in patients with stable angina pectoris. Although statistically not significant, Nifedipine demonstrated a trend in slowing down the development of new atherosclerotic lesions.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>16940720</pmid><doi>10.1159/000095308</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-6312 |
| ispartof | Cardiology, 2007-03, Vol.107 (3), p.165-171 |
| issn | 0008-6312 1421-9751 |
| language | eng |
| recordid | cdi_pubmed_primary_16940720 |
| source | MEDLINE; Karger Journals |
| subjects | Aged Angina pectoris Angina Pectoris - drug therapy Atherosclerosis - drug therapy Atherosclerosis - pathology Calcinosis - drug therapy Calcinosis - pathology Calcium Channel Blockers - therapeutic use Cardiology Coronary Vessels - pathology Drug therapy Female Humans Male Middle Aged Nifedipine - therapeutic use Original Research |
| title | Tracking Coronary Calcification and Atherosclerotic Lesions in Patients with Stable Angina Pectoris Undergoing Nifedipine Therapy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T11%3A14%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Tracking%20Coronary%20Calcification%20and%20Atherosclerotic%20Lesions%20in%20Patients%20with%20Stable%20Angina%20Pectoris%20Undergoing%20Nifedipine%20Therapy&rft.jtitle=Cardiology&rft.au=Motro,%20Michael&rft.aucorp=ACTION%20CC%20side-arm%20study&rft.date=2007-03&rft.volume=107&rft.issue=3&rft.spage=165&rft.epage=171&rft.pages=165-171&rft.issn=0008-6312&rft.eissn=1421-9751&rft_id=info:doi/10.1159/000095308&rft_dat=%3Cproquest_pubme%3E70342414%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=274709067&rft_id=info:pmid/16940720&rfr_iscdi=true |